Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (171) 171
breast cancer (145) 145
female (145) 145
index medicus (140) 140
oncology (138) 138
middle aged (136) 136
aged (104) 104
adult (96) 96
breast neoplasms - drug therapy (92) 92
breast neoplasms - pathology (87) 87
cancer (62) 62
chemotherapy (62) 62
medicine & public health (62) 62
treatment outcome (57) 57
antineoplastic combined chemotherapy protocols - therapeutic use (49) 49
care and treatment (48) 48
metastasis (47) 47
prognosis (42) 42
disease-free survival (41) 41
research (39) 39
cancer research (38) 38
receptor, erbb-2 - metabolism (38) 38
surgery (37) 37
therapy (37) 37
breast neoplasms - mortality (36) 36
analysis (35) 35
clinical trials (35) 35
neoplasm staging (35) 35
survival (34) 34
breast neoplasms - surgery (33) 33
surgical oncology (32) 32
women (30) 30
breast neoplasms - metabolism (28) 28
docetaxel (28) 28
epidermal growth factor (28) 28
patients (28) 28
antineoplastic combined chemotherapy protocols - adverse effects (27) 27
male (27) 27
trial (27) 27
endocrine therapy (26) 26
cancer therapies (25) 25
japan (25) 25
oncology, experimental (25) 25
postmenopausal women (25) 25
trastuzumab (25) 25
cyclophosphamide (23) 23
chemotherapy, adjuvant (22) 22
neoplasm metastasis (22) 22
aged, 80 and over (21) 21
capecitabine (21) 21
estrogen (21) 21
multicenter (21) 21
original (21) 21
performing operations (21) 21
receptors, estrogen - metabolism (21) 21
transporting (21) 21
antimitotic agents (20) 20
antineoplastic agents (20) 20
metastatic breast cancer (20) 20
obstetrics & gynecology (20) 20
tumors (20) 20
cancer patients (19) 19
metastases (19) 19
neoadjuvant therapy (19) 19
original article (19) 19
tamoxifen (19) 19
breast neoplasms - genetics (18) 18
drug administration schedule (18) 18
hematology, oncology and palliative medicine (18) 18
kaplan-meier estimate (18) 18
taxoids - administration & dosage (18) 18
antineoplastic combined chemotherapy protocols - administration & dosage (17) 17
drug therapy (17) 17
erbb-2 protein (17) 17
fluorouracil - administration & dosage (17) 17
lumpectomy (17) 17
medical colleges (17) 17
postmenopause (17) 17
retrospective studies (17) 17
anthracyclines (16) 16
chemistry (16) 16
letrozole (16) 16
paclitaxel (16) 16
toxicity (16) 16
young adult (16) 16
adjuvant treatment (15) 15
combination (15) 15
mastectomy, segmental (15) 15
paclitaxel - administration & dosage (15) 15
survival analysis (15) 15
cyclophosphamide - administration & dosage (14) 14
double-blind method (14) 14
expression (14) 14
human necessities (14) 14
medical prognosis (14) 14
medical research (14) 14
metallurgy (14) 14
pharmacology & pharmacy (14) 14
post-menopause (14) 14
product development (14) 14
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (407) 407
Japanese (36) 36
French (14) 14
German (7) 7
Chinese (1) 1
Korean (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text ISY11-2A new era of preoperative chemotherapy for breast cancer; optimal treatment strategy for patients with residual tumor
by Masuda, Norikazu
Annals of Oncology, ISSN 0923-7534, 10/2017, Volume 28, Issue suppl_9
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
by Cristofanilli, Massimo, Prof and Turner, Nicholas C, MD and Bondarenko, Igor, Prof and Ro, Jungsil, MD and Im, Seock-Ah, MD and Masuda, Norikazu, MD and Colleoni, Marco, MD and DeMichele, Angela, MD and Loi, Sherene, MD and Verma, Sunil, MD and Iwata, Hiroji, MD and Harbeck, Nadia, Prof and Zhang, Ke, PhD and Theall, Kathy Puyana, MD and Jiang, Yuqiu, PhD and Bartlett, Cynthia Huang, MD and Koehler, Maria, MD and Slamon, Dennis, Prof
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 425 - 439
Summary Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was associated with significant... 
Hematology, Oncology and Palliative Medicine | KINASE 4/6 INHIBITOR | SOUTHWEST-ONCOLOGY-GROUP | ONCOLOGY | RESISTANCE | PROGESTERONE-RECEPTOR | MUTATIONS | COMBINATION | AROMATASE INHIBITORS | EXPRESSION | ESTROGEN-RECEPTOR | CHEMOTHERAPY | Piperazines - administration & dosage | Estradiol - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Estradiol - administration & dosage | Treatment Outcome | Breast Neoplasms - drug therapy | Neoplasm Recurrence, Local - pathology | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Neoplasm Metastasis | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Breast Neoplasms - pathology | Adult | Female | Neoplasm Recurrence, Local - genetics | Aged | Mutation | Medical colleges | Care and treatment | Oncology, Experimental | Clinical trials | Breast cancer | Metastasis | Hormones | Research | Antineoplastic agents | Epidemiology | Antimitotic agents | Analysis | Product development | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
by André, Fabrice, Prof and O'Regan, Ruth, Prof and Ozguroglu, Mustafa, Prof and Toi, Masakazu, Prof and Xu, Binghe, Prof and Jerusalem, Guy, Prof and Masuda, Norikazu, MD and Wilks, Sharon, MD and Arena, Francis, MD and Isaacs, Claudine, Prof and Yap, Yoon-Sim, MD and Papai, Zsuzsanna, MD and Lang, Istvan, Prof and Armstrong, Anne, MD and Lerzo, Guillermo, MD and White, Michelle, MD and Shen, Kunwei, Prof and Litton, Jennifer, MD and Chen, David, PhD and Zhang, Yufen, PhD and Ali, Shyanne and Taran, Tetiana, MD and Gianni, Luca, Dr
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 6, pp. 580 - 591
Summary Background Disease progression in patients with HER2-positive breast cancer receiving trastuzumab might be associated with activation of the... 
Hematology, Oncology and Palliative Medicine | CAPECITABINE | ACTIVATION | ONCOLOGY | GROWTH | PTEN | II TRIAL | COMBINATION | PERTUZUMAB | CHEMOTHERAPY | PLUS | PACLITAXEL | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Antibodies, Monoclonal, Humanized - administration & dosage | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Genes, erbB-2 | Aged, 80 and over | Adult | Breast Neoplasms - mortality | Female | Aged | Everolimus | Trastuzumab | Drug Resistance, Neoplasm - drug effects | Clinical trials | Breast cancer | Angiogenesis inhibitors | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
by Baselga, José, Prof and Im, Seock-Ah, Prof and Iwata, Hiroji, MD and Cortés, Javier, MD and De Laurentiis, Michele, MD and Jiang, Zefei, Prof and Arteaga, Carlos L, Prof and Jonat, Walter, Prof and Clemons, Mark, Prof and Ito, Yoshinori, MD and Awada, Ahmad, Prof and Chia, Stephen, MD and Jagiełło-Gruszfeld, Agnieszka, MD and Pistilli, Barbara, MD and Tseng, Ling-Ming, MD and Hurvitz, Sara, MD and Masuda, Norikazu, MD and Takahashi, Masato, MD and Vuylsteke, Peter, MD and Hachemi, Soulef, PhD and Dharan, Bharani, MS and Di Tomaso, Emmanuelle, PhD and Urban, Patrick, MD and Massacesi, Cristian, MD and Campone, Mario, Prof
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 904 - 916
Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark of endocrine therapy-resistant, hormone receptor-positive breast... 
Hematology, Oncology and Palliative Medicine | HETEROGENEITY | WOMEN | PALBOCICLIB | THERAPY | EXEMESTANE | ONCOLOGY | MUTATION | RESISTANCE | COMBINATION | AROMATASE INHIBITORS | PI3K INHIBITOR | Estradiol - analogs & derivatives | Humans | Middle Aged | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Receptors, Estrogen - analysis | Fulvestrant | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Neoplasm Metastasis | Hyperglycemia - chemically induced | DNA, Neoplasm - blood | DNA Mutational Analysis | Exanthema - chemically induced | Postmenopause | Female | Morpholines - adverse effects | Aminopyridines - administration & dosage | Drug Eruptions - etiology | Double-Blind Method | Morpholines - administration & dosage | Estradiol - administration & dosage | Survival Rate | Signal Transduction - genetics | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Retreatment | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Aspartate Aminotransferases - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Clinical trials | Product development | Breast cancer | Postmenopausal women | Hormones | Antineoplastic agents | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
by Chan, Arlene, Prof and Delaloge, Suzette, MD and Holmes, Frankie A, MD and Moy, Beverly, MD and Iwata, Hiroji, MD and Harvey, Vernon J, MD and Robert, Nicholas J, MD and Silovski, Tajana, MD and Gokmen, Erhan, MD and von Minckwitz, Gunter, Prof and Ejlertsen, Bent, MD and Chia, Stephen K L, MD and Mansi, Janine, MD and Barrios, Carlos H, Prof and Gnant, Michael, Prof and Buyse, Marc, ScD and Gore, Ira, MD and Smith, John, MD and Harker, Graydon, MD and Masuda, Norikazu, MD and Petrakova, Katarina, MD and Zotano, Angel Guerrero, MD and Iannotti, Nicholas, MD and Rodriguez, Gladys, MD and Tassone, Pierfrancesco, Prof and Wong, Alvin, PharmD and Bryce, Richard, MBChB and Ye, Yining, PhD and Yao, Bin, MS and Martin, Miguel, Prof and ExteNET Study Grp and ExteNET Study Group
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 367 - 377
Summary Background Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive... 
Hematology, Oncology and Palliative Medicine | LAPATINIB | WOMEN | HERA TRIAL | ONCOLOGY | TYROSINE KINASE INHIBITOR | OPEN-LABEL | MINIMALLY IMPORTANT DIFFERENCES | COMBINATION | ESTROGEN-RECEPTOR | CHEMOTHERAPY | ONCOGENE ADDICTION | Breast Neoplasms - surgery | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Mastectomy - methods | Receptor, ErbB-2 - metabolism | Quinolines - administration & dosage | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Adult | Female | Chemotherapy, Adjuvant | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Internationality | Survival Analysis | Breast Neoplasms - mortality | Aged | Neoplasm Staging | Quinolines - adverse effects | Antimitotic agents | Tyrosine | Medical colleges | Care and treatment | Adjuvant treatment | Clinical trials | Product development | Breast cancer | Metastasis | College teachers | Antineoplastic agents | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
by Robson, Mark and Im, Seock-Ah and Senkus, Elżbieta and Xu, Binghe and Domchek, Susan M and Masuda, Norikazu and Delaloge, Suzette and Li, Wei and Tung, Nadine and Armstrong, Anne and Wu, Wenting and Goessl, Carsten and Runswick, Sarah and Conte, Pierfranco
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 6, pp. 523 - 533
Among patients with metastatic breast cancer and a germline BRCA mutation, daily treatment with the PARP inhibitor olaparib was associated with longer... 
TRIAL | MEDICINE, GENERAL & INTERNAL | SCORES | ABC 3 | PHASE-2 | CARRIERS | INTERNATIONAL CONSENSUS GUIDELINES | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Young Adult | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Chemotherapy, Adjuvant | Genes, BRCA1 | Kaplan-Meier Estimate | Piperazines - therapeutic use | Poly(ADP-ribose) Polymerase Inhibitors - adverse effects | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Disease-Free Survival | Phthalazines - therapeutic use | Breast Neoplasms - genetics | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 | Phthalazines - adverse effects | Treatment outcome | Gene mutations | Analysis | Breast cancer | Genetic aspects | Research | Drug therapy | Medical research | Adenosine | Inhibitor drugs | Metastasis | Cancer therapies | Survival | ErbB-2 protein | Metastases | Chemotherapy | Epidermal growth factor | Ribose | Medical prognosis | Risk assessment | Antitumor activity | Mutation | Drug dosages | Deoxyribonucleic acid--DNA | Vinorelbine | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria
by Katayama, Hiroshi and Kurokawa, Yukinori and Nakamura, Kenichi and Ito, Hiroyuki and Kanemitsu, Yukihide and Masuda, Norikazu and Tsubosa, Yasuhiro and Satoh, Toyomi and Yokomizo, Akira and Fukuda, Haruhiko and Sasako, Mitsuru
Surgery Today, ISSN 0941-1291, 6/2016, Volume 46, Issue 6, pp. 668 - 685
Prior to publication of the Clavien-Dindo classification in 2004, there were no grading definitions for surgical complications in either clinical practice or... 
Clavien-Dindo classification | Medicine & Public Health | Surgical Oncology | Surgery | JCOG postoperative complications criteria (JCOG PC criteria) | Postoperative complications | COLON-CANCER | SURGERY | RANDOMIZED CONTROLLED-TRIAL | Complications and side effects | Complications | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
by Masuda, Norikazu, MD and Sagara, Yasuaki, MD and Kinoshita, Takayuki, MD and Iwata, Hiroji, MD and Nakamura, Seigo, Prof and Yanagita, Yasuhiro, MD and Nishimura, Reiki, MD and Iwase, Hirotaka, Prof and Kamigaki, Shunji, MD and Takei, Hiroyuki, MD and Noguchi, Shinzaburo, Prof
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 4, pp. 345 - 352
Summary Background Aromatase inhibitors have shown increased efficacy compared with tamoxifen in postmenopausal early breast cancer. We aimed to assess the... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | CYCLOPHOSPHAMIDE | ADJUVANT ENDOCRINE THERAPY | METHOTREXATE | FOLLOW-UP | QUALITY-OF-LIFE | POSTMENOPAUSAL WOMEN | COMBINATION | FLUOROURACIL | PLUS ZOLEDRONIC ACID | AROMATASE INHIBITORS | Aromatase Inhibitors - administration & dosage | Neoplasms, Hormone-Dependent - surgery | Breast Neoplasms - surgery | Goserelin - administration & dosage | Triazoles - administration & dosage | Triazoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Premenopause | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Breast Neoplasms - drug therapy | Tamoxifen - administration & dosage | Nitriles - administration & dosage | Breast Neoplasms - pathology | Adult | Female | Neoadjuvant Therapy | Neoplasms, Hormone-Dependent - drug therapy | Neoplasm Staging | Nitriles - adverse effects | Antimitotic agents | Menopause | Clinical trials | Product development | Breast cancer | Postmenopausal women | Tamoxifen | Antineoplastic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The authors reply
by Toi, Masakazu and Masuda, Norikazu and Ohashi, Yasuo
New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 8, pp. 791 - 792
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
by Masuda, Norikazu and Lee, Soo-Jung and Lee, Eun-Sook and Ohtani, Shoichiro and Im, Young-Hyuck and Im, Seock-Ah and Yokota, Isao and Kuroi, Katsumasa and Park, Byeong-Woo and Park, Kyong-Hwa and Kim, Sung-Bae and Kim, Aeree and Yanagita, Yasuhiro and Ohno, Shinji and Takao, Shintaro and Aogi, Kenjiro and Iwata, Hiroji and Jeong, Joon and Sasano, Hironobu and Ohashi, Yasuo and Toi, Masakazu
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2147 - 2159
Patients who complete neoadjuvant chemotherapy for breast cancer without a pathological complete response have a high risk of relapse. A randomized trial... 
PHASE-III TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS CYCLOPHOSPHAMIDE | THERAPY | GASTRIC-CANCER | FOLLOW-UP | TAXANE | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | DOCETAXEL | NEOADJUVANT | Breast Neoplasms - surgery | Humans | Middle Aged | Triple Negative Breast Neoplasms - mortality | Capecitabine - therapeutic use | Hand-Foot Syndrome - etiology | Triple Negative Breast Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Preoperative Care | Antimetabolites, Antineoplastic - therapeutic use | Capecitabine - adverse effects | Chemotherapy, Adjuvant - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Adult | Breast Neoplasms - mortality | Female | Neoadjuvant Therapy | Aged | Receptor, ErbB-2 | Neoplasm Staging | Care and treatment | Usage | Chemotherapy | Breast cancer | Capecitabine | Cancer | Medical research | Invasiveness | Clinical trials | Hand | Survival | ErbB-2 protein | Feet | Epidermal growth factor | Anthracycline | Medical prognosis | Death
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
by Turner, Nicholas C and Slamon, Dennis J and Ro, Jungsil and Bondarenko, Igor and Im, Seock-Ah and Masuda, Norikazu and Colleoni, Marco and DeMichele, Angela and Loi, Sherene and Verma, Sunil and Iwata, Hiroji and Harbeck, Nadia and Loibl, Sibylle and André, Fabrice and Puyana Theall, Kathy and Huang, Xin and Giorgetti, Carla and Huang Bartlett, Cynthia and Cristofanilli, Massimo
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 20, pp. 1926 - 1936
The addition of palbociclib to fulvestrant prolonged overall survival among women with hormone receptor–positive, HER2-negative advanced breast cancer who had... 
WOMEN | MEDICINE, GENERAL & INTERNAL | LETROZOLE | ENDOCRINE THERAPY | ABEMACICLIB | COMBINATION | PROGRESSION | PLUS | Piperazines - administration & dosage | Estradiol - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Humans | Middle Aged | Estradiol - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Fulvestrant | Protein Kinase Inhibitors - administration & dosage | Receptors, Steroid - analysis | Pyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Estradiol - adverse effects | Breast Neoplasms - mortality | Female | Aged | ErbB Receptors - analysis | Cancer patients | Safety and security measures | Breast cancer | Dosage and administration | Drug therapy | Health aspects | Medical research | Statistical analysis | Cyclin-dependent kinases | Endocrine therapy | Metastasis | Cancer therapies | Survival | ErbB-2 protein | Cyclin-dependent kinase 4 | Metastases | Cyclin-dependent kinase | Chemotherapy | Epidermal growth factor | Womens health | Medical prognosis | Mutation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study
by Masuda, Norikazu and Nishimura, Reiki and Takahashi, Masato and Inoue, Kenichi and Ohno, Shinji and Iwata, Hiroji and Mori, Yuko and Hashigaki, Satoshi and Muramatsu, Yasuaki and Nagasawa, Takashi and Umeyama, Yoshiko and Toi, Masakazu
Cancer Science, ISSN 1347-9032, 03/2018, Volume 109, Issue 3, pp. 803 - 813
This single‐arm, open‐label, phase II study in 42 Japanese postmenopausal patients with estrogen receptor‐positive/human epidermal growth factor receptor... 
letrozole | cyclin‐dependent kinase | advanced breast cancer | Japanese | palbociclib | cyclin-dependent kinase | DEPENDENT KINASE 4/6 | ONCOLOGY | INHIBITOR PALBOCICLIB | GUIDELINE | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Postmenopausal women | Research | Drug therapy, Combination | Drug therapy | Antineoplastic agents | Cancer | Plasma | Medical research | Research funding | Menopause | Estrogen receptors | Endocrine therapy | Metastasis | Survival | ErbB-2 protein | Disease control | Patients | Post-menopause | Studies | Stomatitis | Epidermal growth factor | Womens health | Cell cycle | Pharmacokinetics | Drug dosages | Neutropenia | Tumors | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast Cancer
by Sugie, Tomoharu and Kinoshita, Takayuki and Masuda, Norikazu and Sawada, Terumasa and Yamauchi, Akira and Kuroi, Katsumasa and Taguchi, Tetsuya and Bando, Hiroko and Yamashiro, Hiroyasu and Lee, Tecchuu and Shinkura, Nobuhiko and Kato, Hironori and Ikeda, Takafumi and Yoshimura, Kenichi and Ueyama, Hanae and Toi, Masakazu
Annals of Surgical Oncology, ISSN 1068-9265, 1/2016, Volume 23, Issue 1, pp. 44 - 50
This study compared the clinical utility of indocyanine green (ICG) fluorescence and radioisotope (RI) for sentinel lymph node (SLN) detection in breast... 
Oncology | Medicine & Public Health | Surgical Oncology | Surgery | Breast Neoplasms - surgery | Lymph Nodes - pathology | Prognosis | Prospective Studies | Follow-Up Studies | Lymph Nodes - surgery | Coloring Agents | Humans | Middle Aged | Fluorescence | Young Adult | Aged, 80 and over | Adult | Female | Breast Neoplasms - diagnostic imaging | Radiopharmaceuticals | Organotechnetium Compounds | Neoplasm Invasiveness | Indocyanine Green | Breast Neoplasms - pathology | Radionuclide Imaging | Aged | Sentinel Lymph Node Biopsy | Neoplasm Staging | Lymph Nodes - diagnostic imaging | Breast cancer | Comparative analysis | Methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights